Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
1 other identifier
observational
520
1 country
1
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present. The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedFirst Submitted
Initial submission to the registry
January 31, 2023
CompletedFirst Posted
Study publicly available on registry
February 13, 2023
CompletedFebruary 13, 2023
January 1, 2023
11.5 years
January 31, 2023
February 9, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Disease-free survival (DFS)
From the day the patient received surgery to the time the patient was diagnosed with postoperative recurrence, assessed up to 36 months.
Study Arms (2)
Selective extended dissection (SED) group
Standard dissection (SD) group
Interventions
An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.
Eligibility Criteria
Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery
You may qualify if:
- \- 1) Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery.
- \) Patients received radical surgery (R0) and had complete photos or videos of the operation.
You may not qualify if:
- \- 1) The operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection.
- \) Patients with incomplete clinical, pathological, imaging and follow-up information.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 30000, China
Related Publications (1)
Guo X, Song Y, Xu P, Zhu W, Wang H, Zhou Y, Huang C, Hao J, Gao S. Selective extended dissection for pancreaticoduodenectomy is associated with better survival in pancreatic cancer patients: retrospective cohort study. Int J Surg. 2023 Jul 1;109(7):1852-1862. doi: 10.1097/JS9.0000000000000437.
PMID: 37195787DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 31, 2023
First Posted
February 13, 2023
Study Start
January 1, 2011
Primary Completion
July 1, 2022
Study Completion
December 1, 2022
Last Updated
February 13, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will share